Recent Updates
Recently added Catalysts
ATRA Positive Sentiment

Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

Key Takeaway: Atara Biotherapeutics will participate in two investor conferences in March 2020. CEO Pascal Touchon will present at the Cowen 40th Annual Health Care Conference and the Barclays Global Healthcare Conference. Live webcasts of the presentations will be available on the company's website, enhancing investor engagement and visibility.

Market Sentiment Analysis

POSITIVE FACTORS

  • Atara Biotherapeutics is actively engaging with investors.
  • Participation in two notable healthcare conferences highlights company visibility.
  • The company is developing innovative T-cell immunotherapies for serious diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
52.2%
average across 2 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
EBV-specific T cells
Phase 2 · EBV-induced Lymphomas

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon, the Company's President and Chief Executive Officer, will participate at two upcoming investor conferences in March:
Cowen 40thAnnual Health Care ConferenceFireside Chat: Monday, March 2, 2020 at 4:10 pm ESTBoston Marriott Copley Place in Boston, MA
Barclays Global Healthcare ConferenceCompany Presentation: Wednesday, March 11, 2020 at 11:45 am EDTLoews Miami Beach Hotel in Miami Beach, FL
Live audio webcasts will be available by visiting theInvestors & Media – News & Eventssection ofatarabio.com. Archived replays of the webcasts will be available on the Company's website for 14 days following the live webcasts.
About Atara Biotherapeutics, Inc.Atara Biotherapeutics, Inc.(@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel®(tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by our state-of-the-art manufacturing facility in Thousand Oaks, California. For additional information about the company, please visitatarabio.com.

INVESTOR & MEDIA CONTACTS:

MediaKerry Beth DalyHead, Corporate CommunicationsAtara Biotherapeutics516-982-9328kdaly@atarabio.com

InvestorsJohn Craighead, Ph.D.Vice President, Investor Relations & Corporate CommunicationsAtara Biotherapeutics650-410-3012jcraighead@atarabio.com

Frequently Asked Questions

Who is participating in the investor conferences?

Pascal Touchon, the President and CEO of Atara Biotherapeutics, will participate.

When is the Cowen 40th Annual Health Care Conference?

The Cowen conference is on March 2, 2020, at 4:10 pm EST.

Where will the Barclays Global Healthcare Conference be held?

It will take place at the Loews Miami Beach Hotel in Miami Beach, FL.

How can investors access the conference presentations?

Live audio webcasts will be available on Atara's website.

Last updated: Feb 20, 2020